Can I legally order peptides?

Short answer: FDA-approved peptide drugs are legal with a prescription, and "research use only" peptides sold for people to use sit outside the law. In practice, the enforcement actions on record have mostly targeted sellers (their marketing and websites) and compounding pharmacies. Buyers aren't risk-free, though: U.S. Customs has seized shipments addressed to individual recipients, and FDA says personal importation of drugs is illegal in most circumstances. The bigger everyday risk for a buyer is different: nothing in the law checks what's actually in the vial you receive. That's the question this article ends on.

This isn't legal advice. It's what FDA and other regulators have actually published, with a link to every source, so you can check it yourself.

The prescription lane still exists, separately

Several peptides are FDA-approved prescription drugs: tirzepatide as Mounjaro and Zepbound, semaglutide as Ozempic and Wegovy, tesamorelin as Egrifta. Those go through a licensed pharmacy with a prescription, full stop — that's true of any approved drug, not something specific to peptides. Everything below is about the other market: vials sold online as "research use only."

Where enforcement has actually landed: seller marketing, and compounders

FDA has been explicit that an RUO label doesn't decide what a product legally is — actual intended use does, judged by the seller's marketing and website claims. On August 24, 2026, FDA's Center for Drug Evaluation and Research sent warning letters to online peptide sellers on that exact theory. One reads: "Despite statements on your product labeling marketing your products 'for research use only' and 'not for human or veterinary use,' evidence obtained from your website establishes that your products are intended to be drugs for human use" (FDA warning letter, Aug. 24, 2026). That letter flagged semaglutide, tirzepatide, retatrutide and other formulations marketed with therapeutic claims, and FDA sent similar letters to four other online peptide vendors the same day, on the same legal theory (ArentFox Schiff, Aug. 2026). Those letters targeted sellers' claims and marketing.

Shipments are the other place enforcement shows up. In one release, U.S. Customs and Border Protection's Cincinnati office described intercepting roughly 5,000 individual peptide packages, including retatrutide, semaglutide and tirzepatide, shipped from China in mis-manifested cartons and addressed to individual recipients. So the realistic risk for a buyer is less "a warning letter" and more "a package that never arrives," on top of the quality risk below.

The second front is compounding pharmacies, which sit under a completely different rule. FDA had let compounders prepare semaglutide and tirzepatide during a formal drug shortage; once FDA declared the tirzepatide shortage resolved (December 2024) and the semaglutide shortage resolved (February 2025), it set deadlines through May 2025 for compounders to stop (Alston & Bird; Harris Beach Murtha). On April 30, 2026, FDA went further, proposing to permanently exclude semaglutide, tirzepatide and liraglutide from the list outsourcing facilities can use even outside a shortage (Pharmacy Times, 2026). BPC-157 tells a similar story from a different angle: FDA flagged it as a Category 2 safety concern in 2023, blocking compounding pharmacies from using it, then announced on April 15, 2026 that it would remove that flag — which is not the same as approving it for compounding, and FDA's advisory committee later voted, at its July 23–24, 2026 meeting, to recommend adding it to the 503A bulks list, a non-binding vote that still needs HHS approval (NCPA, July 31, 2026). The April announcement is from Frier Levitt, Apr. 16, 2026. Again: this is about what licensed compounding pharmacies may prepare for patients, not about a vial shipped from a research-use storefront.

What none of that gives you as a buyer

Here's the gap that matters more than the legal status itself. An FDA-approved drug from a licensed pharmacy comes with manufacturing controls and batch oversight before it ever reaches you. A vial sold "for research use only" has none of that built in — no agency checks what's actually in it, and if a warning letter eventually lands on the seller, that doesn't get you a refund, an explanation, or even a straight answer about what was in the vial you already have. The legal system's attention is on the seller's marketing; it was never set up to police the contents of your specific order.

That's the entire reason independent, buyer-commissioned lab testing exists as its own category, separate from anything FDA does. A lab report tells you what a warning letter never will: whether a vial is actually pure, whether it matches its labeled amount, and whether a given vendor's track record holds up across multiple tests rather than one. Choosing a vendor with a real body of lab reports behind it — not a perfect-looking storefront — is the closest thing to the oversight an approved drug gets automatically.

Here's who has the strongest independent lab record right now:

For the method behind picking a vendor from that list, see how to judge a peptide supplier; if you already have a vial and want to check it yourself, see how to get a peptide tested. The full, current rankings live at vendor ratings — we track lab reports on 67 vendors as of today, and a vendor needs at least 5 before it's ranked at all, which is worth knowing before you trust any single glowing result. A flawless score built on one or two reports isn't proof of anything; it's a lack of data. So is a vendor whose only supporting evidence is a "best peptide vendors" list — most of those are written by affiliates paid per click, not by anyone who ran a test.

And if a report on a vial you bought comes back bad — underdosed, failed purity, or worse — the law isn't going to be the thing that helps you. Stop using that batch, tell whatever group or forum you found the vendor through, and go back to the vendor with the actual report in hand. Then submit it through our submission form so the next buyer sees it too. That loop — buyers testing, publishing, and warning each other — is the only real enforcement mechanism in this market, and it exists entirely outside anything FDA does.

Personal importation, in FDA's own words

FDA's page on this is direct: "In most circumstances, it is illegal for individuals to import drugs or devices into the U.S. for personal use," largely because foreign products often haven't gone through FDA approval (FDA, Personal Importation, page dated Aug. 18, 2025). We're not covering customs or shipping here, and this isn't a guide to importing anything.

Everything above is US federal law and FDA policy specifically. Other countries classify and regulate peptides differently — what counts as a prescription drug, a controlled research chemical, or something else varies by jurisdiction, and none of this transfers across a border. If you're outside the US, the relevant authority is your own country's health and customs regulators, not FDA.

The question the law can't answer

Legal status and vial quality are separate questions, answered by separate evidence. Whether a product sits in a legal grey area tells you nothing about whether that specific vial is 99% pure or empty — only an independent lab report does that, which is the reason we publish independent lab results, mostly paid for by buyers, in the first place. See what are grey market peptides for how that market is structured, and are grey market peptides safe for what independent lab reports actually show.

This summarizes published FDA positions as of September 28, 2026, and is not legal advice. FDA updates its enforcement priorities and its bulk drug substances list on an ongoing basis — check FDA's current guidance directly for anything you're relying on.